AŁ
Therapeutic Areas
Captor Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CT-03 | Chemotherapy-resistant Acute Myeloid Leukemia (AML); other liquid & solid tumors | Preclinical |
| Undisclosed Degrader (ABM Program) | Colorectal Cancer | Preclinical |
| Undisclosed BID Degraders | Rheumatoid Arthritis; Inflammatory Bowel Disease | Discovery |
| Undisclosed Degraders | Multiple Severe Malignancies | Discovery |
Leadership Team at Captor Therapeutics
MW
Michał Walczak
Chief Executive Officer, Chief Scientific Officer
AP
Anna Pawluk
Chief Operating Officer